September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Differences in anti-vascular endothelial growth factor (anti-VEGF) injection frequency and costs for ranibizumab versus aflibercept in patients with diabetic macular edema (DME)
Author Affiliations & Notes
  • Carlos Quezada Ruiz
    Genentech, Inc., South San Francisco, California, United States
  • Yamina Rajput
    Genentech, Inc., South San Francisco, California, United States
  • Kathleen Wilson
    Truven Health Analytics, Bethesda, Maryland, United States
  • Alice Huang
    Truven Health Analytics, Bethesda, Maryland, United States
  • David M Smith
    Truven Health Analytics, Bethesda, Maryland, United States
  • Helen Varker
    Truven Health Analytics, Bethesda, Maryland, United States
  • Stephen S Johnston
    Truven Health Analytics, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Carlos Quezada Ruiz, Genentech, Inc. (E); Yamina Rajput, Genentech, Inc. (E); Kathleen Wilson, Truven Health Analytics (C); Alice Huang, Truven Health Analytics (C); David Smith, Truven Health Analytics (C); Helen Varker, Truven Health Analytics (C); Stephen Johnston, Truven Health Analytics (C)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2101. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Carlos Quezada Ruiz, Yamina Rajput, Kathleen Wilson, Alice Huang, David M Smith, Helen Varker, Stephen S Johnston; Differences in anti-vascular endothelial growth factor (anti-VEGF) injection frequency and costs for ranibizumab versus aflibercept in patients with diabetic macular edema (DME). Invest. Ophthalmol. Vis. Sci. 2016;57(12):2101.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : To compare the frequency and costs of intravitreal anti-VEGF injections, in treatment-naïve (TN) or previously-treated (PT) patients with DME receiving ranibizumab (RBZ) 0.3 mg vs aflibercept (AFL) 2.0 mg.

Methods : This retrospective study of US Medicare claims data included patients who initiated treatment with RBZ or AFL (index date [ID] August 10, 2012 to July 31, 2015) with the following criteria: aged ≥18 years on ID; 12 months’ continuous eligibility before ID and for 3–12 months following ID without switching to a different anti-VEGF agent. Number of injections and related costs were determined at 3-, 6-, 9-, and 12-month follow-up. Injection frequency and costs for RBZ vs AFL were compared by multivariate regression models. All models were adjusted for patient demographics and clinical characteristics.

Results : In both TN (baseline [BL]: RBZ [N=1,305]; AFL [N=409]) and PT (BL: RBZ [N=756]; AFL [N=575]) patients, there were no statistically significant differences between treatment groups in the frequency of injections at months 3, 6, 9, and 12. However, statistically significant differences in cost, in favor of RBZ, were seen across all time points in both TN and PT patients. For example, in TN patients at 6-months’ follow-up, adjusted injection costs were $3,466 vs $5,979 for RBZ (N=912) and AFL (N=138), respectively; the adjusted cost ratio was 1.73 (95% CI=1.53–1.94), p<0.0001. The adjusted cost ratio was also significantly in favor of RBZ at months 3 and 9 (p<0.0001) and month 12 (p=0.04). Similarly, in PT patients at 6 months, the adjusted injection costs were $3,660 vs $5,759 for RBZ (N=465) and AFL (N=165), respectively; the adjusted cost ratio was 1.57 (95% CI=1.35–1.84), p<0.0001. The adjusted cost ratio was also significantly in favor of RBZ at month 3 (p<0.0001), month 9 (p=0.009) and month 12 (p=0.018).

Conclusions : For each analyzed follow-up period, and for both TN and PT patients, injection frequency did not differ significantly between RBZ and AFL treatments. Importantly, substantial and statistically significant differences (all p<0.05) in the costs of anti-VEGF injections were observed between RBZ and AFL treatments. While the data should be interpreted with caution (decreasing sample size; need for continued study) RBZ was the less costly treatment for DME regardless of follow-up time.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×